RU2007147609A - Составы для эффективной потери веса - Google Patents

Составы для эффективной потери веса Download PDF

Info

Publication number
RU2007147609A
RU2007147609A RU2007147609/15A RU2007147609A RU2007147609A RU 2007147609 A RU2007147609 A RU 2007147609A RU 2007147609/15 A RU2007147609/15 A RU 2007147609/15A RU 2007147609 A RU2007147609 A RU 2007147609A RU 2007147609 A RU2007147609 A RU 2007147609A
Authority
RU
Russia
Prior art keywords
compound
derivative
group
agonist
norepinephrine
Prior art date
Application number
RU2007147609/15A
Other languages
English (en)
Russian (ru)
Inventor
Гэри ТОЛЛЕФСОН (US)
Гэри ТОЛЛЕФСОН
КИННИ Энтони А. Мак (US)
КИННИ Энтони А. Мак
Мишель С. ХИГГИН (US)
Мишель С. ХИГГИН
КОЛЛ Джон М. Мак (US)
КОЛЛ Джон М. Мак
Original Assignee
Ориксиджен Терапьютикс, Инкорпорейтд (Us)
Ориксиджен Терапьютикс, Инкорпорейтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ориксиджен Терапьютикс, Инкорпорейтд (Us), Ориксиджен Терапьютикс, Инкорпорейтд filed Critical Ориксиджен Терапьютикс, Инкорпорейтд (Us)
Publication of RU2007147609A publication Critical patent/RU2007147609A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007147609/15A 2005-07-27 2006-07-24 Составы для эффективной потери веса RU2007147609A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70287705P 2005-07-27 2005-07-27
US60/702,877 2005-07-27

Publications (1)

Publication Number Publication Date
RU2007147609A true RU2007147609A (ru) 2009-09-10

Family

ID=37198787

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007147609/15A RU2007147609A (ru) 2005-07-27 2006-07-24 Составы для эффективной потери веса

Country Status (12)

Country Link
US (1) US20070117827A1 (cg-RX-API-DMAC7.html)
EP (1) EP1907005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009502931A (cg-RX-API-DMAC7.html)
KR (1) KR20080042092A (cg-RX-API-DMAC7.html)
CN (1) CN101237886A (cg-RX-API-DMAC7.html)
AU (1) AU2006275914A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613911A2 (cg-RX-API-DMAC7.html)
CA (1) CA2614539A1 (cg-RX-API-DMAC7.html)
IL (1) IL188442A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008001136A (cg-RX-API-DMAC7.html)
RU (1) RU2007147609A (cg-RX-API-DMAC7.html)
WO (1) WO2007016108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
AU2009249071A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT3222280T (pt) 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물

Also Published As

Publication number Publication date
WO2007016108A1 (en) 2007-02-08
BRPI0613911A2 (pt) 2011-02-22
JP2009502931A (ja) 2009-01-29
CN101237886A (zh) 2008-08-06
AU2006275914A1 (en) 2007-02-08
EP1907005A1 (en) 2008-04-09
US20070117827A1 (en) 2007-05-24
KR20080042092A (ko) 2008-05-14
CA2614539A1 (en) 2007-02-08
MX2008001136A (es) 2008-03-13
IL188442A0 (en) 2008-04-13
WO2007016108B1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
JP2009502931A5 (cg-RX-API-DMAC7.html)
WO2007016108B1 (en) Compositions for affecting weight loss
RU2007103313A (ru) Комбинация бупропина и другого состава для эффективной потери веса
JP4343948B2 (ja) 体重減少に影響を及ぼすための組成物
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
RU96109832A (ru) Синергическое лечение паркинсонизма
RU2008135264A (ru) Терапевтическое средство для воспалительных заболеваний кишечника, содержащее в качестве активного ингредиента производное 2-амино-1,3-пропандиола, или способ лечения воспалительных заболеваний кишечника
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
YU97292A (sh) N-fenilalanil i n-fenilglicil derivati dipeptida l-azetidin-2-karboksilne kiseline
WO2011113005A2 (en) Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo)
CY1112911T1 (el) Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο
HUP0202938A2 (hu) N-aril-2-(szulfonil-amino)-benzamidok mint foszfát-transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények
EA200600188A1 (ru) Производные пиримидин-2,4-диона и их применение в качестве антагонистов рецепторов гонадолиберина
RU2004126093A (ru) Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени
BG107774A (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
CN1652758A (zh) 使用文拉法辛和衍生物治疗胃肠和泌尿生殖疼痛症的方法
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
KR101442525B1 (ko) 무스카린성 수용체 m1 길항제를 이용하여 비만을 치료하는방법
TWI265926B (en) Polymorphic hemisulphate salt of the compound 3-(N-methyl-2-(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole
JP2009521470A5 (cg-RX-API-DMAC7.html)
SI1517909T1 (sl) Novi tetraciklični arilkarbonil indoli, ki imajo afiniteto za serotoninski receptor, uporabni kot terapevtska sredstva, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
Khairallah et al. Potentiation of vascular myotropic responses by metanephrine and other noncatecholamines
Kier et al. Hallucinogenic Agents
RU2005117626A (ru) Улучшенные готовые лекарственные формы, содержащие замещенные производные имидазола
PL334088A1 (en) Novel derivatives of n-benzenesulphonyl-l-proline, methods of obtaining them and pharmaceutic agents

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110124